(-0.46%) 5 048.42 points
(-0.98%) 38 086 points
(-0.64%) 15 612 points
(0.36%) $83.87
(-3.36%) $1.583
(0.19%) $2 347.00
(0.74%) $27.56
(1.09%) $930.50
(0.10%) $0.933
(0.15%) $10.97
(0.08%) $0.800
(0.01%) $92.18
Live Chart Being Loaded With Signals
Brii Biosciences Limited engages in the development of medicines for the treatment of infectious and central nervous system diseases. The company develops BRII-778 and BRII-732, which are in phase I clinical trials for the treatment of HIV patients; BRII-179 and BRII-835, which are in Phase 2 to evaluate the combination of these two HBV mechanisms for Hepatitis B; BRII-179, a recombinant protein-based HBV immunotherapeutic candidate that is in Phase 1b/2a; BRII-835, which has completed Phase-2 for patients with chronic HBV infection; and Amubarvimab/romlusevimab combination therapy for the treatment of COVID-19...
Stats | |
---|---|
Today's Volume | 454 000 |
Average Volume | 4.56M |
Market Cap | 809.90M |
EPS | HKD0 ( 2024-03-25 ) |
Next earnings date | ( HKD0 ) 2024-06-19 |
Last Dividend | HKD0 ( N/A ) |
Next Dividend | HKD0 ( N/A ) |
P/E | -4.27 |
ATR14 | HKD0.00600 (0.54%) |
Volume Correlation
Brii Biosciences Limited Correlation
10 Most Positive Correlations |
---|
10 Most Negative Correlations |
---|
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
Brii Biosciences Limited Correlation - Currency/Commodity
Brii Biosciences Limited Financials
Annual | 2023 |
Revenue: | HKD55.89M |
Gross Profit: | HKD55.89M (100.00 %) |
EPS: | HKD-0.240 |
Q4 | 2023 |
Revenue: | HKD7.90M |
Gross Profit: | HKD7.90M (100.00 %) |
EPS: | HKD0.0104 |
Q3 | 2023 |
Revenue: | HKD7.90M |
Gross Profit: | HKD7.90M (100.00 %) |
EPS: | HKD0.0104 |
Q2 | 2023 |
Revenue: | HKD20.05M |
Gross Profit: | HKD39.40M (196.52 %) |
EPS: | HKD-0.130 |
Financial Reports:
No articles found.
Brii Biosciences Limited
Brii Biosciences Limited engages in the development of medicines for the treatment of infectious and central nervous system diseases. The company develops BRII-778 and BRII-732, which are in phase I clinical trials for the treatment of HIV patients; BRII-179 and BRII-835, which are in Phase 2 to evaluate the combination of these two HBV mechanisms for Hepatitis B; BRII-179, a recombinant protein-based HBV immunotherapeutic candidate that is in Phase 1b/2a; BRII-835, which has completed Phase-2 for patients with chronic HBV infection; and Amubarvimab/romlusevimab combination therapy for the treatment of COVID-19. It also develops BRII-296 for the treatment of PPD; BRII-297 for treatment of various depressive disorders; BRII-636, BRII-672, and BRII-693 for the treatment of multi-drug resistant/extensive drug resistant (MDR/XDR) gram-negative infections; and BRII-658 for the treatment of MDR/XDR tuberculosis and non-tuberculosis mycobacteria. The company was incorporated in 2017 and is based in Beijing, China.
About Live Signals
The live signals presented on this page help determine when to BUY or SELL NA. The signals have upwards of a 1-minute delay; like all market signals, there is a chance for error or mistakes.
The live trading signals are not definite, and getagraph.com hold no responsibility for any action taken upon these signals, as described in the Terms of Use. The signals are based on a wide range of technical analysis indicators